A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy. The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rosenfeld, Myrna R, Ye, Xiaobu, Supko, Jeffrey G, Desideri, Serena, Grossman, Stuart A, Brem, Steven, Mikkelson, Tom, Wang, Daniel, Chang, Yunyoung C, Hu, Janice, McAfee, Quentin, Fisher, Joy, Troxel, Andrea B, Piao, Shengfu, Heitjan, Daniel F, Tan, Kay-See, Pontiggia, Laura, O’Dwyer, Peter J, Davis, Lisa E, Amaravadi, Ravi K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Landes Bioscience 2014
Gaiak:
Clinical Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4203513/
https://ncbi.nlm.nih.gov/pubmed/24991840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/auto.28984
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak